Kiniksa Pharmaceuticals International PLC
KNSA32.945USD
+0.965+3.02%
交易中 （美東）報價延遲15分鐘
2.44B總市值
虧損本益比TTM
關於 Kiniksa Pharmaceuticals International PLC 公司
Kiniksa Pharmaceuticals International, plc 是一家商業階段的生物製藥公司，專注於發現、收購、開發和商業化治療藥物，用於治療患有嚴重衰弱性疾病且醫療需求未得到滿足的患者。其免疫調節資產組合 ARCALYST、abiprubart 和 mavrilimumab 基於強大的生物學原理或經過驗證的機制，針對一系列醫療資源不足的心血管和自身免疫疾病，並具有差異化潛力。ARCALYST 是一種白細胞介素-1α 和白細胞介素-1β 細胞因子誘捕器。ARCALYST 用於治療複發性心包炎並降低成人和 12 歲及以上兒童的復發風險。 ARCALYST 還被批准用於治療冷吡啉相關週期性綜合徵 (CAPS)，包括家族性冷自身炎症綜合徵 (FCAS) 和 Muckle-Wells 綜合徵，以及維持白細胞介素-1受體拮抗劑缺乏症的緩解。
公司簡介
公司代碼KNSA
公司名稱Kiniksa Pharmaceuticals International PLC
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
員工數量315
證券類型Ordinary Share
年結日May 24
公司地址23 Old Bond Street, Floor 3
城市LONDON
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編WIS 4PZ
電話
網址https://www.kiniksa.com/
公司代碼KNSA
上市日期May 24, 2018
CEOMr. Sanjiv K. (Sanj) Patel
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
18.47K
+6.34%
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Independent Director
Independent Director
12.55K
+33.85%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
12.55K
--
Mr. Ross Moat
Mr. Ross Moat
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
9.41K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Sanjiv K. (Sanj) Patel
Mr. Sanjiv K. (Sanj) Patel
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
206.47K
--
Mr. Thomas Robert (Tom) Malley
Mr. Thomas Robert (Tom) Malley
Independent Director
Independent Director
84.51K
+3.90%
Dr. John F. Paolini, M.D., Ph.D.
Dr. John F. Paolini, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
57.40K
--
Mr. Eben Tessari
Mr. Eben Tessari
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
49.16K
-20.14%
Mr. Mark Ragosa
Mr. Mark Ragosa
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
27.01K
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Lead Independent Director
Lead Independent Director
24.21K
+63.16%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月22日 週四
更新時間: 5月22日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
持股股東
持股股東
佔比
Rubric Capital Management LP
8.99%
The Vanguard Group, Inc.
7.71%
Baker Bros. Advisors LP
6.48%
BlackRock Institutional Trust Company, N.A.
5.78%
Tang Capital Management, LLC
4.87%
Other
66.16%
股東類型
持股股東
佔比
Hedge Fund
41.14%
Investment Advisor
27.15%
Investment Advisor/Hedge Fund
25.63%
Individual Investor
3.86%
Research Firm
2.27%
Pension Fund
0.59%
Bank and Trust
0.30%
Insurance Company
0.11%
Family Office
0.10%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
393
42.78M
98.41%
-554.60K
2025Q1
407
42.98M
101.69%
-650.43K
2024Q4
391
41.95M
99.92%
-5.07M
2024Q3
382
42.52M
104.55%
-472.80K
2024Q2
354
38.32M
94.71%
-9.35M
2024Q1
340
41.61M
104.40%
+110.03K
2023Q4
319
36.70M
103.36%
-5.01M
2023Q3
318
37.56M
105.96%
-4.22M
2023Q2
312
35.54M
100.99%
-4.88M
2023Q1
303
35.17M
100.37%
-5.41M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Rubric Capital Management LP
3.38M
7.99%
+764.14K
+29.18%
Mar 31, 2025
The Vanguard Group, Inc.
3.35M
7.91%
+151.60K
+4.74%
Mar 31, 2025
Baker Bros. Advisors LP
2.82M
6.66%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
5.94%
-39.60K
-1.55%
Mar 31, 2025
Tang Capital Management, LLC
2.12M
5%
+1.49M
+237.03%
Mar 31, 2025
Braidwell LP
1.96M
4.64%
-1.49M
-43.14%
Mar 31, 2025
Point72 Asset Management, L.P.
1.15M
2.71%
+1.15M
--
Mar 31, 2025
Pictet Asset Management Ltd.
1.13M
2.68%
--
--
Mar 31, 2025
Fairmount Funds Management LLC
1.10M
2.6%
+1.10M
--
Mar 31, 2025
Desnick (Robert)
1.05M
2.48%
--
--
Apr 08, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Products ETF
1.92%
First Trust Active Factor Small Cap ETF
0.54%
VictoryShares Small Cap Free Cash Flow ETF
0.53%
iShares Health Innovation Active ETF
0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.15%
WisdomTree US SmallCap Fund
0.15%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
Fidelity Enhanced Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.04%
查看更多
Virtus LifeSci Biotech Products ETF
佔比1.92%
First Trust Active Factor Small Cap ETF
佔比0.54%
VictoryShares Small Cap Free Cash Flow ETF
佔比0.53%
iShares Health Innovation Active ETF
佔比0.24%
iShares MSCI USA Small-Cap Min Vol Factor ETF
佔比0.15%
WisdomTree US SmallCap Fund
佔比0.15%
ProShares Ultra Nasdaq Biotechnology
佔比0.13%
Invesco Nasdaq Biotechnology ETF
佔比0.13%
Fidelity Enhanced Small Cap ETF
佔比0.11%
iShares Micro-Cap ETF
佔比0.04%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
